Evidence map›Paper›PMID 26207185›Full record

ArticleEnvironmental science. Nano2015

Catalytic Properties and Biomedical Applications of Cerium Oxide Nanoparticles.

Carl Walkey, Soumen Das, Sudipta Seal, Joseph Erlichman, Karin Heckman, Lina Ghibelli, Enrico Traversa, James F McGinnis, William T Self

Abstract read
In one paragraph

Article in Environmental science. Nano, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Carbon@CeORSC advances · 2026
    Article
  4. Immunomodulatory Nanozymes as Programmable Redox-Immune Set-Point Regulators.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  5. Article
  6. Article
  7. Template-Free Morphology Engineering of CeOMolecules (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Radioprotective Potency of Nanoceria.Current radiopharmaceuticals · 2024
    Review
  17. Review
  18. Article
  19. Article
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Carl WalkeyIntegrated Nanotechnology and Biomedical Sciences Laboratory, Terrence Donnelly Building, University of Toronto, 160 College St., Toronto, ON M5S 3G9, Canada.
Soumen DasAdvanced Materials Processing and Analysis Centre, Nanoscience Technology Center, University of Central Florida, Orlando, FL, US.
Sudipta SealAdvanced Materials Processing and Analysis Centre, Nanoscience Technology Center, University of Central Florida, Orlando, FL, US.
Joseph ErlichmanDepartment of Biology, St. Lawrence University, Johnson Hall of Science, 23 Romoda Drive, Canton, NY 13617.
Karin HeckmanDepartment of Biology, St. Lawrence University, Johnson Hall of Science, 23 Romoda Drive, Canton, NY 13617.
Lina GhibelliDepartment of Biology, Università di Roma Tor Vergata, Via della Ricerca Scientifica, 00133 Roma, Italy.
Enrico TraversaKing Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Saudi Arabia.
James F McGinnisDean A. McGee Eye Institute, Department of Ophthalmology, 608 Stanton L. Young, Blvd., Oklahoma City, OK 73126.
William T SelfBurnett School of Biomedical Science, College of Medicine, University of Central Florida, Orlando, Florida 32816.

Funding

UNDERSTANDING THE ROLE OF RETINOL DEHYDROGENASES RDH11 AND RDH12 IN VISIONP20RR017703 · NCRR · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MANDAL, NAWAJES · 2002 to 2011
$23.6M
P30-CENTER CORE GRANT FOR VISION RESEARCHP30EY021725 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Michelle C Callegan · 2011 to 2026
$10.5M
CORE--MOLECULAR BIOLOGYP30EY012190 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI ANDERSON, ROBERT E · 1999 to 2009
$5.2M
Prolonged Inhibition of Pathologic Neovascularization by Catalytic AntioxidantsR01EY022111 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MCGINNIS, JAMES FRANCIS · 2012 to 2015
$2.2M
Prevention of Inherited Retinal Diseases by Therapeutic Rare Earth NanoparticlesR01EY018724 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MCGINNIS, JAMES FRANCIS · 2009 to 2010
$738k
Pharmacokinetics of Therapeutic Nanoparticles in the CNSR21EY018306 · NEI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI MCGINNIS, JAMES FRANCIS · 2007 to 2009
$555k
NCRR NIH HHS P20 RR017703NEI NIH HHS P30 EY012190NEI NIH HHS P30 EY021725NEI NIH HHS R01 EY018724NEI NIH HHS R01 EY022111NEI NIH HHS R21 EY018306
6 · The paper itself

Abstract

Cerium oxide nanoparticles (Nanoceria) have shown promise as catalytic antioxidants in the test tube, cell culture models and animal models of disease. However given the reactivity that is well established at the surface of these nanoparticles, the biological utilization of Nanoceria as a therapeutic still poses many challenges. Moreover the form that these particles take in a biological environment, such as the changes that can occur due to a protein corona, are not well established. This review aims to summarize the existing literature on biological use of Nanoceria, and to raise questions about what further study is needed to apply this interesting catalytic material to biomedical applications. These questions include: 1) How does preparation, exposure dose, route and experimental model influence the reported effects of Nanoceria in animal studies? 2) What are the considerations to develop Nanoceria as a therapeutic agent in regards to these parameters? 3) What biological targets of reactive oxygen species (ROS) and reactive nitrogen species (RNS) are relevant to this targeting, and how do these properties also influence the safety of these nanomaterials?

Identifiers

PMID26207185
PMCPMC4508017

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.